



M Joerger

Contact

M Joerger

Units

Medizinische Onkologie und Hämatologie

Publications (6)

Schmid S, Jochum W, Padberg B, Demmer I, Mertz K, Joerger M, Britschgi C, Matter M, Rothschild S, Omlin A. How to read a next-generation sequencing report-what oncologists need to know. *ESMO Open* 2022; 7:100570.

Gachechiladze M, Überall I, Skanderová D, Matchavariani J, Ibrahim M, Shani I, Smičková P, Kolek V, Cierna L, Kleine-Tebbe J, Stahel R, Joerger M, Soltermann A, Škarda J. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. *Lung Cancer* 2021; 156:129-135.

Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). *Br J Clin Pharmacol* 2015; 80:128-38.

Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C. Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. *Invest New Drugs* 2015; 33:472-9.

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. *Lung Cancer* 2014; 87:85-7.

Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich T, Largiader C, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. *Cancer Chemother Pharmacol* 2012; 71:361-70.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch